The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer.

ABSTRACT: Biochemically recurrent prostate cancer represents a stage of prostate cancer where conventional (continued on next page) computed tomography and technetium Tc 99m bone scan imaging are unable to detect disease after curative intervention despite rising prostate-specific antigen. There is no clear standard of care and no systemic therapy has been shown to improve survival. Immunotherapy-based treatments potentially are attractive options relative to androgen deprivation therapy due to the generally more favorable side-effect profile. Biochemically recurrent prostate cancer patients have a low tumor burden and likely lymph node-based disease, which may make them more likely to respond to immunotherapy.

SUBMITTER: Bilusic M 

PROVIDER: S-EPMC8177734 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature